Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efavaleukin alfa in moderately to severely active ulcerative colitis
NCT05672199Phase 2Terminated
- Sponsor
- Amgen
- Start
- Apr 2023
- Primary completion
- Oct 2024
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 13
01
Overview
A Phase 2 trial of efavaleukin alfa in ulcerative colitis (UC), sponsored by Amgen. Started Apr 2023; status: terminated.
02
Drugs
efavaleukin alfa
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05672199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05672199.